Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma.

ABSTRACT: Immune checkpoint inhibitors (ICI) have drastically changed the landscape of metastatic melanoma management, thus significantly improving survival. Clinically, assessing treatment response may be challenging in a portion of cases due to a massive influx of immune cells into the tumor microenvironment, causing a transient increase in the target lesion size. This phenomenon, coined pseudoprogression, can occur in 5-10% of metastatic patients, and it is commonly followed by a tumor regression. Its incidence, however, may be underestimated, given its ephemeral nature and often being documented in visceral metastatic lesions, which are only assessed by imaging scans every 2-3 months. More recently, ICI has been studied in the neoadjuvant setting, yielding durable pathological responses in patie

SUBMITTER: Garcia D 

PROVIDER: S-EPMC8255661 | biostudies-literature | 2021 May-Aug

REPOSITORIES: biostudies-literature